Structural basis of targeting the exportin CRM1 in cancer

Cells

Volumn 4, Issue 3, 2015, Pages 538-568

  Dickmanns, Achim ^a   Monecke, Thomas ^a   Ficner, Ralf ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cancer; CRM1; Drugs; Exportin1; Inhibitor; NES; Nuclear transport; XPO1

Indexed keywords

EXPORTIN 1;

AMINO ACID SEQUENCE; CELL CYCLE REGULATION; CHROMOSOME SEGREGATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; GENETIC TRANSCRIPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NEOPLASM; NONHUMAN; PHOSPHORYLATION; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURAL PROTEOMICS; TRANSACTIVATION ASSAY;

EID: 84962028956     PISSN: None     EISSN: 20734409     Source Type: Journal    
DOI: 10.3390/cells4030538     Document Type: Review

References (239)

1. Dobbelstein, M.; Moll, U. Targeting tumour-supportive cellular machineries in anticancer drug development. Nat. Rev. Drug Discov. 2014, 13, 179–196.
2. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70.
3. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674.
4. Goldstein, I.; Madar, S.; Rotter, V. Cancer research, a field on the verge of a paradigm shift? Trends Mol. Med. 2012, 18, 299–303.
5. Weinberg, R.A. Coming full circle-from endless complexity to simplicity and back again. Cell 2014, 157, 267–271.
6. Faustino, R.S.; Nelson, T.J.; Terzic, A.; Perez-Terzic, C. Nuclear transport: Target for therapy. Clin. Pharmacol. Ther. 2007, 81, 880–886.
7. Turner, J.G.; Dawson, J.; Sullivan, D.M. Nuclear export of proteins and drug resistance in cancer. Biochem. Pharmacol. 2012, 83, 1021–1032.
8. Hill, R.; Cautain, B.; de Pedro, N.; Link, W. Targeting nucleocytoplasmic transport in cancer therapy. Oncotarget 2014, 5, 11–28.
9. Stommel, J.M.; Marchenko, N.D.; Jimenez, G.S.; Moll, U.M.; Hope, T.J.; Wahl, G.M. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by nes masking. EMBO J. 1999, 18, 1660–1672.
10. Foo, R.S.; Nam, Y.J.; Ostreicher, M.J.; Metzl, M.D.; Whelan, R.S.; Peng, C.F.; Ashton, A.W.; Fu, W.; Mani, K.; Chin, S.F. et al. Regulation of p53 tetramerization and nuclear export by arc. Proc. Natl. Acad. Sci. USA 2007, 104, 20826–20831.
11. Muller, P.A.; Vousden, K.H. Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell 2014, 25, 304–317.
12. Vousden, K.H.; Prives, C. P53 and prognosis: New insights and further complexity. Cell 2005, 120, 7–10.
13. Jiao, W.; Datta, J.; Lin, H.M.; Dundr, M.; Rane, S.G. Nucleocytoplasmic shuttling of the retinoblastoma tumor suppressor protein via cdk phosphorylation-dependent nuclear export. J. Biol. Chem. 2006, 281, 38098–38108.
14. Kowalik, A.; Kopczynski, J.; Wypiorkiewicz, E.; Gozdz, S.; Mezyk, R.; Siedlecki, J.A. Active transport of rb protein from the nucleus to the cytoplasm as one of the development mechanisms of her2-positive breast cancer. Pol. J. Pathol. Off. J. Pol. Soc. Pathol. 2013, 64, 9–14.
15. Mittnacht, S.; Lees, J.A.; Desai, D.; Harlow, E.; Morgan, D.O.; Weinberg, R.A. Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J. 1994, 13, 118–127.
16. Stokke, T.; Erikstein, B.K.; Smedshammer, L.; Boye, E.; Steen, H.B. The retinoblastoma gene product is bound in the nucleus in early g1 phase. Exp. Cell Res. 1993, 204, 147–155.
17. Neufeld, K.L.; Nix, D.A.; Bogerd, H.; Kang, Y.; Beckerle, M.C.; Cullen, B.R.; White, R.L. Adenomatous polyposis coli protein contains two nuclear export signals and shuttles between the nucleus and cytoplasm. Proc. Natl. Acad. Sci. USA 2000, 97, 12085–12090.
18. Neufeld, K.L.; White, R.L. Nuclear and cytoplasmic localizations of the adenomatous polyposis coli protein. Proc. Natl. Acad. Sci. USA 1997, 94, 3034–3039.
19. Powell, S.M.; Zilz, N.; Beazer-Barclay, Y.; Bryan, T.M.; Hamilton, S.R.; Thibodeau, S.N.; Vogelstein, B.; Kinzler, K.W. APC mutations occur early during colorectal tumorigenesis. Nature 1992, 359, 235–237.
20. Henderson, B.R.; Fagotto, F. The ins and outs of APC and β-catenin nuclear transport. EMBO Rep. 2002, 3, 834–839.
21. Jamieson, C.; Sharma, M.; Henderson, B.R. Targeting the beta-catenin nuclear transport pathway in cancer. Semin. Cancer Biol. 2014, 27, 20–29.
22. Crabtree, G.R.; Olson, E.N. Nfat signaling: Choreographing the social lives of cells. Cell 2002, 109, S67–S79.
23. Mancini, M.; Toker, A. Nfat proteins: Emerging roles in cancer progression. Nat. Rev. Cancer 2009, 9, 810–820.
24. Muller, M.R.; Rao, A. Nfat, immunity and cancer: A transcription factor comes of age. Nat. Rev. Immunol. 2010, 10, 645–656.
25. Pan, M.G.; Xiong, Y.; Chen, F. Nfat gene family in inflammation and cancer. Curr. Mol. Med. 2013, 13, 543–554.
26. Qin, J.J.; Nag, S.; Wang, W.; Zhou, J.; Zhang, W.D.; Wang, H.; Zhang, R. Nfat as cancer target: Mission possible? Biochim. Biophys. Acta 2014, 1846, 297–311.
27. Lugo, T.G.; Pendergast, A.M.; Muller, A.J.; Witte, O.N. Tyrosine kinase activity and transformation potency of Bcr-Abl oncogene products. Science 1990, 247, 1079–1082.
28. Cilloni, D.; Saglio, G. Molecular pathways: Bcr-Abl. Clin. Cancer Res. 2012, 18, 930–937.
29. Drake, J.M.; Lee, J.K.; Witte, O.N. Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer. Mol. Cell Biol. 2014, 34, 1722–1732.
30. Brohawn, S.G.; Partridge, J.R.; Whittle, J.R.; Schwartz, T.U. The nuclear pore complex has entered the atomic age. Structure 2009, 17, 1156–1168.
31. Hurt, E.; Beck, M. Towards understanding nuclear pore complex architecture and dynamics in the age of integrative structural analysis. Curr. Opin. Cell Biol. 2015, 34, 31–38.
32. Kabachinski, G.; Schwartz, T.U. The nuclear pore complex—Structure and function at a glance. J. Cell Sci. 2015, 128, 423–429.
33. Andrade, M.A.; Bork, P. Heat repeats in the huntington’s disease protein. Nat. Genet. 1995, 11, 115–116.
34. Andrade, M.A.; Perez-Iratxeta, C.; Ponting, C.P. Protein repeats: Structures, functions, and evolution. J. Struct. Biol. 2001, 134, 117–131.
35. Izaurralde, E.; Kutay, U.; von Kobbe, C.; Mattaj, I.W.; Gorlich, D. The asymmetric distribution of the constituents of the ran system is essential for transport into and out of the nucleus. EMBO J. 1997, 16, 6535–6547.
36. Ohtsubo, M.; Okazaki, H.; Nishimoto, T. The rcc1 protein, a regulator for the onset of chromosome condensation locates in the nucleus and binds to DNA. J. Cell Biol. 1989, 109, 1389–1397.
37. Bischoff, F.R.; Maier, G.; Tilz, G.; Ponstingl, H. A 47-kda human nuclear protein recognized by antikinetochore autoimmune sera is homologous with the protein encoded by rcc1, a gene implicated in onset of chromosome condensation. Proc. Natl. Acad. Sci. USA 1990, 87, 8617–8621.
38. Uchida, S.; Sekiguchi, T.; Nishitani, H.; Miyauchi, K.; Ohtsubo, M.; Nishimoto, T. Premature chromosome condensation is induced by a point mutation in the hamster rcc1 gene. Mol. Cell Biol. 1990, 10, 577–584.
39. Smith, A.E.; Slepchenko, B.M.; Schaff, J.C.; Loew, L.M.; Macara, I.G. Systems analysis of ran transport. Science 2002, 295, 488–491.
40. Kalab, P.; Weis, K.; Heald, R. Visualization of a ran-gtp gradient in interphase and mitotic xenopus egg extracts. Science 2002, 295, 2452–2456.
41. Bischoff, F.R.; Klebe, C.; Kretschmer, J.; Wittinghofer, A.; Ponstingl, H. RanGAP1 induces GTPase activity of nuclear ras-related ran. Proc. Natl. Acad. Sci. USA 1994, 91, 2587–2591.
42. Mahajan, R.; Delphin, C.; Guan, T.; Gerace, L.; Melchior, F. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 1997, 88, 97–107.
43. Matunis, M.J.; Coutavas, E.; Blobel, G. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J. Cell Biol. 1996, 135, 1457–1470.
44. Culjkovic-Kraljacic, B.; Baguet, A.; Volpon, L.; Amri, A.; Borden, K.L. The oncogene eIF4e reprograms the nuclear pore complex to promote mrna export and oncogenic transformation. Cell Rep. 2012, 2, 207–215.
45. Culjkovic-Kraljacic, B.; Borden, K.L. Aiding and abetting cancer: Mrna export and the nuclear pore. Trends Cell Biol. 2013, 23, 328–335.
46. Adachi, Y.; Yanagida, M. Higher order chromosome structure is affected by cold-sensitive mutations in a schizosaccharomyces pombe gene CRM1+ which encodes a 115-kd protein preferentially localized in the nucleus and its periphery. J. Cell Biol. 1989, 108, 1195–1207.
47. Fornerod, M.; Boer, J.; van Baal, S.; Morreau, H.; Grosveld, G. Interaction of cellular proteins with the leukemia specific fusion proteins dek-can and set-can and their normal counterpart, the nucleoporin can. Oncogene 1996, 13, 1801–1808.
48. Fornerod, M.; van Deursen, J.; van Baal, S.; Reynolds, A.; Davis, D.; Murti, K.G.; Fransen, J.; Grosveld, G. The human homologue of yeast CRM1 is in a dynamic subcomplex with can/Nup214 and a novel nuclear pore component Nup88. EMBO J. 1997, 16, 807–816.
49. Fornerod, M.; Ohno, M.; Yoshida, M.; Mattaj, I.W. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997, 90, 1051–1060.
50. Fukuda, M.; Asano, S.; Nakamura, T.; Adachi, M.; Yoshida, M.; Yanagida, M.; Nishida, E. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 1997, 390, 308–311.
51. Neville, M.; Stutz, F.; Lee, L.; Davis, L.I.; Rosbash, M. The importin-beta family member CRM1p bridges the interaction between rev and the nuclear pore complex during nuclear export. Curr. Biol. 1997, 7, 767–775.
52. Ossareh-Nazari, B.; Bachelerie, F.; Dargemont, C. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science 1997, 278, 141–144.
53. Stade, K.; Ford, C.S.; Guthrie, C.; Weis, K. Exportin 1 (CRM1p) is an essential nuclear export factor. Cell 1997, 90, 1041–1050.
54. Kehlenbach, R.H.; Dickmanns, A.; Gerace, L. Nucleocytoplasmic shuttling factors including ran and CRM1 mediate nuclear export of nfat in vitro. J. Cell Biol. 1998, 141, 863–874.
55. Fischer, U.; Huber, J.; Boelens, W.C.; Mattaj, I.W.; Luhrmann, R. The HIV-1 rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular rnas. Cell 1995, 82, 475–483.
56. Wen, W.; Meinkoth, J.L.; Tsien, R.Y.; Taylor, S.S. Identification of a signal for rapid export of proteins from the nucleus. Cell 1995, 82, 463–473.
57. Fu, S.C.; Huang, H.C.; Horton, P.; Juan, H.F. Validness: A database of validated leucine-rich nuclear export signals. Nucleic Acids Res. 2013, 41, D338–D343.
58. Xu, D.; Farmer, A.; Collett, G.; Grishin, N.V.; Chook, Y.M. Sequence and structural analyses of nuclear export signals in the nesdb database. Mol. Biol. Cell 2012, 23, 3677–3693.
59. Ohno, M.; Segref, A.; Bachi, A.; Wilm, M.; Mattaj, I.W. Phax, a mediator of u snrna nuclear export whose activity is regulated by phosphorylation. Cell 2000, 101, 187–198.
60. Segref, A.; Mattaj, I.W.; Ohno, M. The evolutionarily conserved region of the U snRNA export mediator phax is a novel rna-binding domain that is essential for u snrna export. RNA 2001, 7, 351–360.
61. Wolff, B.; Sanglier, J.J.; Wang, Y. Leptomycin b is an inhibitor of nuclear export: Inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) rev protein and rev-dependent mrna. Chem. Biol. 1997, 4, 139–147.
62. Booth, D.S.; Cheng, Y.; Frankel, A.D. The export receptor CRM1 forms a dimer to promote nuclear export of HIV RNA. eLife 2014, 3, e04121, doi:10.7554/eLife.04121.
63. Roscioli, E.; di Francesco, L.; Bolognesi, A.; Giubettini, M.; Orlando, S.; Harel, A.; Schinina, M.E.; Lavia, P. Importin-beta negatively regulates multiple aspects of mitosis including RanGAP1 recruitment to kinetochores. J. Cell Biol. 2012, 196, 435–450.
64. Di Fiore, B.; Ciciarello, M.; Lavia, P. Mitotic functions of the Ran-GTPase network: The importance of being in the right place at the right time. Cell Cycle 2004, 3, 305–313.
65. Arnaoutov, A.; Azuma, Y.; Ribbeck, K.; Joseph, J.; Boyarchuk, Y.; Karpova, T.; McNally, J.; Dasso, M. CRM1 is a mitotic effector of ran-gtp in somatic cells. Nat. Cell Biol. 2005, 7, 626–632.
66. Wang, W.; Budhu, A.; Forgues, M.; Wang, X.W. Temporal and spatial control of nucleophosmin by the ran-CRM1 complex in centrosome duplication. Nat. Cell Biol. 2005, 7, 823–830.
67. Torosantucci, L.; de Luca, M.; Guarguaglini, G.; Lavia, P.; Degrassi, F. Localized rangtp accumulation promotes microtubule nucleation at kinetochores in somatic mammalian cells. Mol. Biol. Cell 2008, 19, 1873–1882.
68. Roscioli, E.; Bolognesi, A.; Guarguaglini, G.; Lavia, P. Ran control of mitosis in human cells: Gradients and local signals. Biochem. Soc. Trans. 2010, 38, 1709–1714.
69. Neuber, A.; Franke, J.; Wittstruck, A.; Schlenstedt, G.; Sommer, T.; Stade, K. Nuclear export receptor XPO1/CRM1 is physically and functionally linked to the spindle pole body in budding yeast. Mol. Cell Biol. 2008, 28, 5348–5358.
70. Dong, X.; Biswas, A.; Suel, K.E.; Jackson, L.K.; Martinez, R.; Gu, H.; Chook, Y.M. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 2009, 458, 1136–1141.
71. Monecke, T.; Guttler, T.; Neumann, P.; Dickmanns, A.; Gorlich, D.; Ficner, R. Crystal structure of the nuclear export receptor CRM1 in complex with snurportin1 and rangtp. Science 2009, 324, 1087–1091.
72. Monecke, T.; Dickmanns, A.; Ficner, R. Allosteric control of the exportin CRM1 unraveled by crystal structure analysis. FEBS J. 2014, 281, 4179–4194.
73. Zachariae, U.; Grubmuller, H. A highly strained nuclear conformation of the exportin CSE1P revealed by molecular dynamics simulations. Structure 2006, 14, 1469–1478.
74. Zachariae, U.; Grubmuller, H. Importin-beta: Structural and dynamic determinants of a molecular spring. Structure 2008, 16, 906–915.
75. Monecke, T.; Haselbach, D.; Voβ, B.; Russek, A.; Neumann, A.; Thomson, E.; Hurt, E.; Zachariae, U.; Stark, H.; Grubmüller, H. et al. Structural basis for cooperativity of CRM1 export complex formation. Proc. Natl. Acad. Sci. USA 2013, 110, 960–965.
76. Dolker, N.; Blanchet, C.E.; Voss, B.; Haselbach, D.; Kappel, C.; Monecke, T.; Svergun, D.I.; Stark, H.; Ficner, R.; Zachariae, U. et al. Structural determinants and mechanism of mammalian CRM1 allostery. Structure 2013, 21, 1350–1360.
77. Saito, N.; Matsuura, Y. A 2.1-A-resolution crystal structure of unliganded CRM1 reveals the mechanism of autoinhibition. J. Mol. Biol. 2013, 425, 350–364.
78. Fox, A.M.; Ciziene, D.; McLaughlin, S.H.; Stewart, M. Electrostatic interactions involving the extreme C terminus of nuclear export factor CRM1 modulate its affinity for cargo. J. Biol. Chem. 2011, 286, 29325–29335.
79. Petosa, C.; Schoehn, G.; Askjaer, P.; Bauer, U.; Moulin, M.; Steuerwald, U.; Soler-Lopez, M.; Baudin, F.; Mattaj, I.W.; Muller, C.W. Architecture of CRM1/exportin1 suggests how cooperativity is achieved during formation of a nuclear export complex. Mol. Cell 2004, 16, 761–775.
80. Guttler, T.; Madl, T.; Neumann, P.; Deichsel, D.; Corsini, L.; Monecke, T.; Ficner, R.; Sattler, M.; Gorlich, D. Nes consensus redefined by structures of pki-type and rev-type nuclear export signals bound to CRM1. Nat. Struct. Mol. Biol. 2010, 17, 1367–1376.
81. Gorlich, D.; Dabrowski, M.; Bischoff, F.R.; Kutay, U.; Bork, P.; Hartmann, E.; Prehn, S.; Izaurralde, E. A novel class of rangtp binding proteins. J. Cell Biol. 1997, 138, 65–80.
82. Koyama, M.; Matsuura, Y. An allosteric mechanism to displace nuclear export cargo from CRM1 and rangtp by ranbp1. EMBO J. 2010, 29, 2002–2013.
83. Matunis, M.J.; Wu, J.; Blobel, G. Sumo-1 modification and its role in targeting the Ran-GTPase-activating protein, RanGAP1, to the nuclear pore complex. J. Cell Biol. 1998, 140, 499–509.
84. Strasser, A.; Dickmanns, A.; Luhrmann, R.; Ficner, R. Structural basis for M3G-cap-mediated nuclear import of spliceosomal usnrnps by snurportin1. EMBO J. 2005, 24, 2235–2243.
85. Paraskeva, E.; Izaurralde, E.; Bischoff, F.R.; Huber, J.; Kutay, U.; Hartmann, E.; Luhrmann, R.; Gorlich, D. CRM1-mediated recycling of snurportin 1 to the cytoplasm. J. Cell Biol. 1999, 145, 255–264.
86. Rodriguez, J.A.; Henderson, B.R. Identification of a functional nuclear export sequence in BRCA1. J. Biol. Chem. 2000, 275, 38589–38596.
87. Hwang, C.Y.; Kim, I.Y.; Kwon, K.S. Cytoplasmic localization and ubiquitination of p21(cip1) by reactive oxygen species. Biochem. Biophys. Res. Commun. 2007, 358, 219–225.
88. Benzeno, S.; Diehl, J.A. C-terminal sequences direct cyclin d1-CRM1 binding. J. Biol. Chem. 2004, 279, 56061–56066.
89. Henderson, B.R. Nuclear-cytoplasmic shuttling of APC regulates β-catenin subcellular localization and turnover. Nat. Cell Biol. 2000, 2, 653–660.
90. Rosin-Arbesfeld, R.; Townsley, F.; Bienz, M. The APC tumour suppressor has a nuclear export function. Nature 2000, 406, 1009–1012.
91. Bartholomeusz, G.; Wu, Y.; Ali Seyed, M.; Xia, W.; Kwong, K.Y.; Hortobagyi, G.; Hung, M.C. Nuclear translocation of the pro-apoptotic BCL-2 family member bok induces apoptosis. Mol. Carcinog. 2006, 45, 73–83.
92. Brunet, A.; Kanai, F.; Stehn, J.; Xu, J.; Sarbassova, D.; Frangioni, J.V.; Dalal, S.N.; de Caprio, J.A.; Greenberg, M.E.; Yaffe, M.B. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J. Cell Biol. 2002, 156, 817–828.
93. Latre de Late, P.; Pepin, A.; Assaf-Vandecasteele, H.; Espinasse, C.; Nicolas, V.; Asselin-Labat, M.L.; Bertoglio, J.; Pallardy, M.; Biola-Vidamment, A. Glucocorticoid-induced leucine zipper (GILZ) promotes the nuclear exclusion of FOXO3 in a CRM1-dependent manner. J. Biol. Chem. 2010, 285, 5594–5605.
94. Howell, J.J.; Stoffel, M. Nuclear export-independent inhibition of FOXA2 by insulin. J. Biol. Chem. 2009, 284, 24816–24824.
95. Falini, B.; Bolli, N.; Shan, J.; Martelli, M.P.; Liso, A.; Pucciarini, A.; Bigerna, B.; Pasqualucci, L.; Mannucci, R.; Rosati, R. et al. Both carboxy-terminus nes motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMC+ AML. Blood 2006, 107, 4514–4523.
96. Yu, Y.; Maggi, L.B., Jr.; Brady, S.N.; Apicelli, A.J.; Dai, M.S.; Lu, H.; Weber, J.D. Nucleophosmin is essential for ribosomal protein l5 nuclear export. Mol. Cell Biol. 2006, 26, 3798–3809.
97. Suetsugu, S.; Takenawa, T. Translocation of n-wasp by nuclear localization and export signals into the nucleus modulates expression of HSP90. J. Biol. Chem. 2003, 278, 42515–42523.
98. Mirski, S.E.; Bielawski, J.C.; Cole, S.P. Identification of functional nuclear export sequences in human topoisomerase IIα and β. Biochem. Biophys. Res. Commun. 2003, 306, 905–911.
99. Turner, J.G.; Engel, R.; Derderian, J.A.; Jove, R.; Sullivan, D.M. Human topoisomerase IIα nuclear export is mediated by two CRM-1-dependent nuclear export signals. J. Cell Sci. 2004, 117, 3061–3071.
100. Mirski, S.E.; Sparks, K.E.; Friedrich, B.; Kohler, M.; Mo, Y.Y.; Beck, W.T.; Cole, S.P. Topoisomerase II binds importin α isoforms and exportin/CRM1 but does not shuttle between the nucleus and cytoplasm in proliferating cells. Exp. Cell Res. 2007, 313, 627–637.
101. Arregi, I.; Falces, J.; Olazabal-Herrero, A.; Alonso-Marino, M.; Taneva, S.G.; Rodriguez, J.A.; Urbaneja, M.A.; Banuelos, S. Leukemia-associated mutations in nucleophosmin alter recognition by CRM1: Molecular basis of aberrant transport. PLoS ONE 2015, 10, e0130610.
102. Ishida, N.; Hara, T.; Kamura, T.; Yoshida, M.; Nakayama, K.; Nakayama, K.I. Phosphorylation of p27kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J. Biol. Chem. 2002, 277, 14355–14358.
103. Ishida, N.; Hara, T.; Kamura, T.; Yoshida, M.; Nakayama, K.; Nakayama, K.I. Phosphorylation of p27kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J. Biol. Chem. 2015, 290, 6754, doi:10.1074/jbc.A114.100762.
104. Connor, M.K.; Kotchetkov, R.; Cariou, S.; Resch, A.; Lupetti, R.; Beniston, R.G.; Melchior, F.; Hengst, L.; Slingerland, J.M. CRM1/ran-mediated nuclear export of p27(kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol. Biol. Cell 2003, 14, 201–213.
105. Zhang, Y.; Xiong, Y. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 2001, 292, 1910–1915.
106. Santiago, A.; Li, D.; Zhao, L.Y.; Godsey, A.; Liao, D. P53 sumoylation promotes its nuclear export by facilitating its release from the nuclear export receptor CRM1. Mol. Biol. Cell 2013, 24, 2739–2752.
107. Lohrum, M.A.; Woods, D.B.; Ludwig, R.L.; Balint, E.; Vousden, K.H. C-terminal ubiquitination of p53 contributes to nuclear export. Mol. Cell Biol. 2001, 21, 8521–8532.
108. Inoue, T.; Geyer, R.K.; Howard, D.; Yu, Z.K.; Maki, C.G. MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding. J. Biol. Chem. 2001, 276, 45255–45260.
109. Craig, E.; Zhang, Z.K.; Davies, K.P.; Kalpana, G.V. A masked nes in INI1/HSNF5 mediates HCRM1-dependent nuclear export: Implications for tumorigenesis. EMBO J. 2002, 21, 31–42.
110. Zhu, J.; McKeon, F. NF-AT activation requires suppression of CRM1-dependent export by calcineurin (see comments). Nature 1999, 398, 256–260.
111. Jeyasekharan, A.D.; Liu, Y.; Hattori, H.; Pisupati, V.; Jonsdottir, A.B.; Rajendra, E.; Lee, M.; Sundaramoorthy, E.; Schlachter, S.; Kaminski, C.F. et al. A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization. Nat. Struct. Mol. Biol. 2013, 20, 1191–1198.
112. Nitiss, J.L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 2009, 9, 338–350.
113. Nitiss, J.L. DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer 2009, 9, 327–337.
114. Wang, J.C. Cellular roles of DNA topoisomerases: A molecular perspective. Nat. Rev. Mol. Cell Biol. 2002, 3, 430–440.
115. Engel, R.; Valkov, N.I.; Gump, J.L.; Hazlehurst, L.; Dalton, W.S.; Sullivan, D.M. The cytoplasmic trafficking of DNA topoisomerase IIα correlates with etoposide resistance in human myeloma cells. Exp. Cell Res. 2004, 295, 421–431.
116. Valkov, N.I.; Sullivan, D.M. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. Semin. Hematol. 1997, 34, 48–62.
117. Turner, J.G.; Marchion, D.C.; Dawson, J.L.; Emmons, M.F.; Hazlehurst, L.A.; Washausen, P.; Sullivan, D.M. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res. 2009, 69, 6899–6905.
118. Turner, J.G.; Dawson, J.; Emmons, M.F.; Cubitt, C.L.; Kauffman, M.; Shacham, S.; Hazlehurst, L.A.; Sullivan, D.M. CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo. J. Cancer 2013, 4, 614–625.
119. Jin, Y.; Xu, X.L.; Yang, M.C.; Wei, F.; Ayi, T.C.; Bowcock, A.M.; Baer, R. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. Proc. Natl. Acad. Sci. USA 1997, 94, 12075–12080.
120. Baer, R.; Ludwig, T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr. Opin. Genet. Dev. 2002, 12, 86–91.
121. Fabbro, M.; Rodriguez, J.A.; Baer, R.; Henderson, B.R. BARD1 induces BRCA1 intranuclear foci formation by increasing ring-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export. J. Biol. Chem. 2002, 277, 21315–21324.
122. Scully, R.; Chen, J.; Ochs, R.L.; Keegan, K.; Hoekstra, M.; Feunteun, J.; Livingston, D.M. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997, 90, 425–435.
123. Rodriguez, J.A.; Schuchner, S.; Au, W.W.; Fabbro, M.; Henderson, B.R. Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1. Oncogene 2004, 23, 1809–1820.
124. Thompson, M.E.; Robinson-Benion, C.L.; Holt, J.T. An amino-terminal motif functions as a second nuclear export sequence in BRCA1. J. Biol. Chem. 2005, 280, 21854–21857.
125. Fabbro, M.; Henderson, B.R. Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp. Cell Res. 2003, 282, 59–69.
126. Rodriguez, J.A.; Span, S.W.; Ferreira, C.G.; Kruyt, F.A.; Giaccone, G. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein survivin. Exp. Cell Res. 2002, 275, 44–53.
127. Knauer, S.K.; Kramer, O.H.; Knosel, T.; Engels, K.; Rodel, F.; Kovacs, A.F.; Dietmaier, W.; Klein-Hitpass, L.; Habtemichael, N.; Schweitzer, A. et al. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J. 2007, 21, 207–216.
128. Conway, E.M.; Pollefeyt, S.; Cornelissen, J.; DeBaere, I.; Steiner-Mosonyi, M.; Ong, K.; Baens, M.; Collen, D.; Schuh, A.C. Three differentially expressed survivin cdna variants encode proteins with distinct antiapoptotic functions. Blood 2000, 95, 1435–1442.
129. Uren, A.G.; Wong, L.; Pakusch, M.; Fowler, K.J.; Burrows, F.J.; Vaux, D.L.; Choo, K.H. Survivin and the inner centromere protein incenp show similar cell-cycle localization and gene knockout phenotype. Curr. Biol. 2000, 10, 1319–1328.
130. Knauer, S.K.; Bier, C.; Habtemichael, N.; Stauber, R.H. The survivin-CRM1 interaction is essential for chromosomal passenger complex localization and function. EMBO Rep. 2006, 7, 1259–1265.
131. Polyak, K.; Lee, M.H.; Erdjument-Bromage, H.; Koff, A.; Roberts, J.M.; Tempst, P.; Massague, J. Cloning of p27kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994, 78, 59–66.
132. Rivard, N.; L’Allemain, G.; Bartek, J.; Pouyssegur, J. Abrogation of p27kip1 by cdna antisense suppresses quiescence (G0 state) in fibroblasts. J. Biol. Chem. 1996, 271, 18337–18341.
133. Coats, S.; Flanagan, W.M.; Nourse, J.; Roberts, J.M. Requirement of p27kip1 for restriction point control of the fibroblast cell cycle. Science 1996, 272, 877–880.
134. Bouchard, C.; Thieke, K.; Maier, A.; Saffrich, R.; Hanley-Hyde, J.; Ansorge, W.; Reed, S.; Sicinski, P.; Bartek, J.; Eilers, M. Direct induction of cyclin D2 by myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999, 18, 5321–5333.
135. Perez-Roger, I.; Kim, S.H.; Griffiths, B.; Sewing, A.; Land, H. Cyclins D1 and D2 mediate MYC-induced proliferation via sequestration of p27(kip1) and p21(cip1). EMBO J. 1999, 18, 5310–5320.
136. Serres, M.P.; Zlotek-Zlotkiewicz, E.; Concha, C.; Gurian-West, M.; Daburon, V.; Roberts, J.M.; Besson, A. Cytoplasmic p27 is oncogenic and cooperates with RAS both in vivo and in vitro. Oncogene 2011, 30, 2846–2858.
137. Sherr, C.J.; Roberts, J.M. Cdk inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13, 1501–1512.
138. Besson, A.; Assoian, R.K.; Roberts, J.M. Regulation of the cytoskeleton: An oncogenic function for CDK inhibitors? Nat. Rev. Cancer 2004, 4, 948–955.
139. Etchin, J.; Sanda, T.; Mansour, M.R.; Kentsis, A.; Montero, J.; Le, B.T.; Christie, A.L.; McCauley, D.; Rodig, S.J.; Kauffman, M. et al. Kpt-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br. J. Haematol. 2013, 161, 117–127.
140. Wang, Y.; Wang, Y.; Xiang, J.; Ji, F.; Deng, Y.; Tang, C.; Yang, S.; Xi, Q.; Liu, R.; Di, W. Knockdown of CRM1 inhibits the nuclear export of p27(kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer. Cancer Lett. 2014, 343, 6–13.
141. Noske, A.; Weichert, W.; Niesporek, S.; Roske, A.; Buckendahl, A.C.; Koch, I.; Sehouli, J.; Dietel, M.; Denkert, C. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/XPO1 is a prognostic factor in human ovarian cancer. Cancer 2008, 112, 1733–1743.
142. Huang, W.Y.; Yue, L.; Qiu, W.S.; Wang, L.W.; Zhou, X.H.; Sun, Y.J. Prognostic value of CRM1 in pancreas cancer. Clin. Investig. Med. 2009, 32, 315–321.
143. Azmi, A.S.; Aboukameel, A.; Bao, B.; Sarkar, F.H.; Philip, P.A.; Kauffman, M.; Shacham, S.; Mohammad, R.M. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology 2013, 144, 447–456.
144. Inoue, H.; Kauffman, M.; Shacham, S.; Landesman, Y.; Yang, J.; Evans, C.P.; Weiss, R.H. CRM1 blockade by selective inhibitors of nuclear export (sine) attenuates kidney cancer growth. J. Urol. 2012, 189, 2317–2326.
145. Van der Watt, P.J.; Maske, C.P.; Hendricks, D.T.; Parker, M.I.; Denny, L.; Govender, D.; Birrer, M.J.; Leaner, V.D. The karyopherin proteins, CRM1 and karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Intern. J. Cancer 2009, 124, 1829–1840.
146. Zhou, F.; Qiu, W.; Yao, R.; Xiang, J.; Sun, X.; Liu, S.; Lv, J.; Yue, L. CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas. Med. Oncol. 2013, 30, 726.
147. Yao, H. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol. Rep. 2009, 21, 229–235.
148. Shen, A.; Wang, Y.; Zhao, Y.; Zou, L.; Sun, L.; Cheng, C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 2009, 65, 153–159.
149. Lapalombella, R.; Sun, Q.; Williams, K.; Tangeman, L.; Jha, S.; Zhong, Y.; Goettl, V.; Mahoney, E.; Berglund, C.; Gupta, S. et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012, 120, 4621–4634.
150. Kojima, K.; Kornblau, S.M.; Ruvolo, V.; Dilip, A.; Duvvuri, S.; Davis, R.E.; Zhang, M.; Wang, Z.; Coombes, K.R.; Zhang, N. et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 2013, 121, 4166–4174.
151. Zhang, K.; Wang, M.; Tamayo, A.T.; Shacham, S.; Kauffman, M.; Lee, J.; Zhang, L.; Ou, Z.; Li, C.; Sun, L. et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp. Hematol. 2013, 41, 67–78.
152. Schmidt, J.; Braggio, E.; Kortuem, K.M.; Egan, J.B.; Zhu, Y.X.; Xin, C.S.; Tiedemann, R.E.; Palmer, S.E.; Garbitt, V.M.; McCauley, D. et al. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia 2013, 27, 2357–2365.
153. Tai, Y.T.; Landesman, Y.; Acharya, C.; Calle, Y.; Zhong, M.Y.; Cea, M.; Tannenbaum, D.; Cagnetta, A.; Reagan, M.; Munshi, A.A. et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications. Leukemia 2014, 28, 155–165
154. Pathria, G.; Wagner, C.; Wagner, S.N. Inhibition of CRM1-mediated nucleocytoplasmic transport: Triggering human melanoma cell apoptosis by perturbing multiple cellular pathways. J. Investig. Dermatol. 2012, 132, 2780–2790.
155. Ranganathan, P.; Yu, X.; Na, C.; Santhanam, R.; Shacham, S.; Kauffman, M.; Walker, A.; Klisovic, R.; Blum, W.; Caligiuri, M. et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 2012, 120, 1765–1773.
156. Etchin, J.; Sun, Q.; Kentsis, A.; Farmer, A.; Zhang, Z.C.; Sanda, T.; Mansour, M.R.; Barcelo, C.; McCauley, D.; Kauffman, M. et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 2013, 27, 66–74.
157. Caceres-Gorriti, K.Y.; Carmona, E.; Barres, V.; Rahimi, K.; Letourneau, I.J.; Tonin, P.N.; Provencher, D.; Mes-Masson, A.M. Ran nucleo-cytoplasmic transport and mitotic spindle assembly partners xpo7 and tpx2 are new prognostic biomarkers in serous epithelial ovarian cancer. PLoS ONE 2014, 9, e91000.
158. Zhu, J.; Wang, Y.; Huang, H.; Yang, Q.; Cai, J.; Wang, Q.; Gu, X.; Xu, P.; Zhang, S.; Li, M. et al. Upregulation of kpnbeta1 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis. Tumour Biol. 2015, doi:10.1007/s13277-015-3839-7.
159. Zhang, P.; Yang, X.; Ma, X.; Ingram, D.R.; Lazar, A.J.; Torres, K.E.; Pollock, R.E. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. Mol. Cancer 2015, 14, 55, doi:10.1186/s12943-015-0325-1.
160. Zhang, P.; Garnett, J.; Creighton, C.J.; Al Sannaa, G.A.; Igram, D.R.; Lazar, A.; Liu, X.; Liu, C.; Pollock, R.E. EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. J. Pathol. 2014, 232, 308–318.
161. Martens-de Kemp, S.R.; Nagel, R.; Stigter-van Walsum, M.; van der Meulen, I.H.; van Beusechem, V.W.; Braakhuis, B.J.; Brakenhoff, R.H. Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer. Clin. Cancer Res. 2013, 19, 1994–2003.
162. Kuusisto, H.V.; Jans, D.A. Hyper-dependence of breast cancer cell types on the nuclear transporter importin β1. Biochim. Biophys. Acta 2015, 1853, 1870–1878.
163. Christiansen, A.; Dyrskjot, L. The functional role of the novel biomarker karyopherin α2 (KPNA2) in cancer. Cancer Lett. 2013, 331, 18–23.
164. Fan, H.; Lu, Y.; Qin, H.; Zhou, Y.; Gu, Y.; Zhou, J.; Wang, X.; Fan, D. High ran level is correlated with poor prognosis in patients with colorectal cancer. Int J. Clin. Oncol. 2013, 18, 856–863.
165. Lu, Y.; Zhao, X.; Li, K.; Luo, G.; Nie, Y.; Shi, Y.; Zhou, Y.; Ren, G.; Feng, B.; Liu, Z. et al. Thioredoxin-like protein 2 is overexpressed in colon cancer and promotes cancer cell metastasis by interaction with ran. Antioxid. Redox Signal. 2013, 19, 899–911.
166. Deng, L.; Lu, Y.; Zhao, X.; Sun, Y.; Shi, Y.; Fan, H.; Liu, C.; Zhou, J.; Nie, Y.; Wu, K. et al. Ran-GTPase protein promotes human pancreatic cancer proliferation by deregulating the expression of survivin and cell cycle proteins. Biochem. Biophys. Res. Commun. 2013, 440, 322–329.
167. Chang, K.C.; Chang, W.C.; Chang, Y.; Hung, L.Y.; Lai, C.H.; Yeh, Y.M.; Chou, Y.W.; Chen, C.H. Ran-GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma. PLoS ONE 2013, 8, e79863.
168. Yuen, H.F.; Chan, K.K.; Grills, C.; Murray, J.T.; Platt-Higgins, A.; Eldin, O.S.; O’Byrne, K.; Janne, P.; Fennell, D.A.; Johnston, P.G. et al. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/MTORC1 and Ras/MEK/ERK pathways. Clin. Cancer Res. 2012, 18, 380–391.
169. Soderholm, J.F.; Bird, S.L.; Kalab, P.; Sampathkumar, Y.; Hasegawa, K.; Uehara-Bingen, M.; Weis, K.; Heald, R. Importazole, a small molecule inhibitor of the transport receptor importin-β. ACS Chem. Biol. 2011, 6, 700–708.
170. Kudo, N.; Khochbin, S.; Nishi, K.; Kitano, K.; Yanagida, M.; Yoshida, M.; Horinouchi, S. Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins. J. Biol. Chem. 1997, 272, 29742–29751.
171. Murakami, N.; Ye, Y.; Kawanishi, M.; Aoki, S.; Kudo, N.; Yoshida, M.; Nakayama, E.E.; Shioda, T.; Kobayashi, M. New rev-transport inhibitor with anti-HIV activity from valerianae radix. Bioorg. Med. Chem. Lett. 2002, 12, 2807–2810.
172. Kudo, N.; Matsumori, N.; Taoka, H.; Fujiwara, D.; Schreiner, E.P.; Wolff, B.; Yoshida, M.; Horinouchi, S. Leptomycin b inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc. Natl. Acad. Sci. USA 1999, 96, 9112–9117.
173. Kudo, N.; Wolff, B.; Sekimoto, T.; Schreiner, E.P.; Yoneda, Y.; Yanagida, M.; Horinouchi, S.; Yoshida, M. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp. Cell Res. 1998, 242, 540–547.
174. Hamamoto, T.; Gunji, S.; Tsuji, H.; Beppu, T. Leptomycins a and b, new antifungal antibiotics. I. Taxonomy of the producing strain and their fermentation, purification and characterization. J. Antibiot. (Tokyo) 1983, 36, 639–645.
175. Hamamoto, T.; Seto, H.; Beppu, T. Leptomycins A and B, new antifungal antibiotics. II. Structure elucidation. J. Antibiot. (Tokyo) 1983, 36, 646–650.
176. Hayakawa, Y.; Adachi, K.; Komeshima, N. New antitumor antibiotics. J. Antibiot. (Tokyo) 1987, 40, 1349–1352.
177. Hayakawa, Y.; Sohda, K.Y.; Shin-Ya, K.; Hidaka, T.; Seto, H. Anguinomycins C and D, new antitumor antibiotics with selective cytotoxicity against transformed cells. J. Antibiot. (Tokyo) 1995, 48, 954–961.
178. Bonazzi, S.; Eidam, O.; Guttinger, S.; Wach, J.Y.; Zemp, I.; Kutay, U.; Gademann, K. Anguinomycins and derivatives: Total syntheses, modeling, and biological evaluation of the inhibition of nucleocytoplasmic transport. J. Am. Chem. Soc. 2010 132, 1432–1442.
179. Bonazzi, S.; Guttinger, S.; Zemp, I.; Kutay, U.; Gademann, K. Total synthesis, configuration, and biological evaluation of anguinomycin C. Angew. Chem. Int. Ed. 2007, 46, 8707–8710.
180. Schummer, D.; Gerth, K.; Reichenbach, H.; Hofle, G. Antibiotics from gliding bacteria 63. Ratjadone—A new antifungal metabolite from sorangium-cellulosum. Liebigs Ann. 1995, 685–688.
181. Gerth, K.; Schummer, D.; Hofle, G.; Irschik, H.; Reichenbach, H. Ratjadon: A new antifungal compound from sorangium cellulosum (myxobacteria) production, physio-chemical and biological properties. J. Antibiot. (Tokyo) 1995, 48, 973–976.
182. Kalesse, M.; Christmann, M.; Bhatt, U.; Quitschalle, M.; Claus, E.; Saeed, A.; Burzlaff, A.; Kasper, C.; Haustedt, L.O.; Hofer, E. et al. The chemistry and biology of ratjadone. ChemBioChem 2001, 2, 709–714.
183. Williams, D.R.; Ihle, D.C.; Plummer, S.V. Total synthesis of (−)-ratjadone. Org. Lett. 2001, 3, 1383–1386.
184. Koster, M.; Lykke-Andersen, S.; Elnakady, Y.A.; Gerth, K.; Washausen, P.; Hofle, G.; Sasse, F.; Kjems, J.; Hauser, H. Ratjadones inhibit nuclear export by blocking CRM1/exportin 1. Exp. Cell Res. 2003, 286, 321–331.
185. Meissner, T.; Krause, E.; Vinkemeier, U. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms. FEBS Lett. 2004, 576, 27–30.
186. Fleta-Soriano, E.; Martinez, J.P.; Hinkelmann, B.; Gerth, K.; Washausen, P.; Diez, J.; Frank, R.; Sasse, F.; Meyerhans, A. The myxobacterial metabolite ratjadone a inhibits HIV infection by blocking the rev/CRM1-mediated nuclear export pathway. Microb. Cell Factories 2014, 13, 17, doi:10.1186/1475-2859-13-17.
187. Sun, Q.; Carrasco, Y.P.; Hu, Y.; Guo, X.; Mirzaei, H.; Macmillan, J.; Chook, Y.M. Nuclear export inhibition through covalent conjugation and hydrolysis of leptomycin B by CRM1. Proc. Natl. Acad. Sci. USA 2013, 110, 1303–1308.
188. Roberts, B.J.; Hamelehle, K.L.; Sebolt, J.S.; Leopold, W.R. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic Ci-940 and its hydroxy analog (pd 114,721). Cancer Chemother. Pharmacol. 1986, 16, 95–101.
189. Newlands, E.S.; Rustin, G.J.; Brampton, M.H. Phase i trial of elactocin. Br. J.Cancer 1996, 74, 648–649.
190. Mutka, S.C.; Yang, W.Q.; Dong, S.D.; Ward, S.L.; Craig, D.A.; Timmermans, P.B.; Murli, S. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 2009, 69, 510–517.
191. Daelemans, D.; Afonina, E.; Nilsson, J.; Werner, G.; Kjems, J.; De Clercq, E.; Pavlakis, G.N.; Vandamme, A.M. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc. Natl. Acad. Sci. USA 2002, 99, 14440–14445.
192. Van Neck, T.; Pannecouque, C.; Vanstreels, E.; Stevens, M.; Dehaen, W.; Daelemans, D. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: Structure-activity relationship and mechanism of action. Bioorg. Med. Chem. 2008, 16, 9487–9497.
193. Haines, J.D.; Herbin, O.; de la Hera, B.; Vidaurre, O.G.; Moy, G.A.; Sun, Q.; Fung, H.Y.; Albrecht, S.; Alexandropoulos, K.; McCauley, D. et al. Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination. Nat. Neurosci. 2015, 18, 511–520.
194. Wang, S.; Han, X.; Wang, J.; Yao, J.; Shi, Y. Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts. PLoS ONE 2014, 9, e89848.
195. Walker, C.J.; Oaks, J.J.; Santhanam, R.; Neviani, P.; Harb, J.G.; Ferenchak, G.; Ellis, J.J.; Landesman, Y.; Eisfeld, A.K.; Gabrail, N.Y. et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in pH+ leukemias. Blood 2013, 122, 3034–3044.
196. London, C.A.; Bernabe, L.F.; Barnard, S.; Kisseberth, W.C.; Borgatti, A.; Henson, M.; Wilson, H.; Jensen, K.; Ito, D.; Modiano, J.F. et al. Preclinical evaluation of the novel, orally bioavailable selective inhibitor of nuclear export (sine) KPT-335 in spontaneous canine cancer: Results of a phase I study. PLoS ONE 2014, 9, e87585.
197. Hilliard, M.; Frohnert, C.; Spillner, C.; Marcone, S.; Nath, A.; Lampe, T.; Fitzgerald, D.J.; Kehlenbach, R.H. The anti-inflammatory prostaglandin 15-deoxy-δ(12,14)-pgj2 inhibits CRM1-dependent nuclear protein export. J. Biol. Chem. 2010, 285, 22202–22210.
198. Niu, M.; Wu, S.; Mao, L.; Yang, Y. CRM1 is a cellular target of curcumin: New insights for the myriad of biological effects of an ancient spice. Traffic 2013, 14, 1042–1052.
199. Aggarwal, B.B.; Kumar, A.; Bharti, A.C. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res. 2003, 23, 363–398.
200. Sharma, R.A.; Euden, S.A.; Platton, S.L.; Cooke, D.N.; Shafayat, A.; Hewitt, H.R.; Marczylo, T.H.; Morgan, B.; Hemingway, D.; Plummer, S.M. et al. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin. Cancer Res. 2004, 10, 6847–6854.
201. Silva, A.L.; Rech, S.B.; von Poser, G.L. Quantitative determination of valepotriates from valeriana native to south brazil. Planta Medica 2002, 68, 570–572.
202. Tamura, S.; Shimizu, N.; Fujiwara, K.; Kaneko, M.; Kimura, T.; Murakami, N. Bioisostere of valtrate, anti-HIV principle by inhibition for nuclear export of rev. Bioorg. Med. Chem. Lett. 2010, 20, 2159–2162.
203. Liu, X.; Niu, M.; Xu, X.; Cai, W.; Zeng, L.; Zhou, X.; Yu, R.; Xu, K. CRM1 is a direct cellular target of the natural anti-cancer agent plumbagin. J. Pharmacol. Sci. 2014, 124, 486–493.
204. Niu, M.; Xu, X.; Shen, Y.; Yao, Y.; Qiao, J.; Zhu, F.; Zeng, L.; Liu, X.; Xu, K. Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity. Chem. Biol. Interact. 2015, 237, 66–72.
205. Chen, W.Y.; Wu, C.C.; Lan, Y.H.; Chang, F.R.; Teng, C.M.; Wu, Y.C. Goniothalamin induces cell cycle-specific apoptosis by modulating the redox status in MDA-MB-231 cells. Eur. J. Pharmacol. 2005, 522, 20–29.
206. Wach, J.Y.; Guttinger, S.; Kutay, U.; Gademann, K. The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport. Bioorg. Med. Chem. Lett. 2010, 20, 2843–2846.
207. De Fatima, A.; Kohn, L.K.; Antonio, M.A.; de Carvalho, J.E.; Pilli, R.A. (R)-goniothalamin: Total syntheses and cytotoxic activity against cancer cell lines. Bioorg. Med. Chem. 2005, 13, 2927–2933.
208. Al-Qubaisi, M.; Rozita, R.; Yeap, S.K.; Omar, A.R.; Ali, A.M.; Alitheen, N.B. Selective cytotoxicity of goniothalamin against hepatoblastoma HEPG2 cells. Molecules 2011, 16, 2944–2959.
209. Chiu, C.C.; Liu, P.L.; Huang, K.J.; Wang, H.M.; Chang, K.F.; Chou, C.K.; Chang, F.R.; Chong, I.W.; Fang, K.; Chen, J.S. et al. Goniothalamin inhibits growth of human lung cancer cells through DNA damage, apoptosis, and reduced migration ability. J. Agric. Food Chem. 2011, 59, 4288–4293.
210. Ye, Y.; Li, B. 1ʹs-1ʹ-acetoxychavicol acetate isolated from alpinia galanga inhibits human immunodeficiency virus type 1 replication by blocking rev transport. J. Gen. Virol. 2006, 87, 2047–2053.
211. Tamura, S.; Shiomi, A.; Kaneko, M.; Ye, Y.; Yoshida, M.; Yoshikawa, M.; Kimura, T.; Kobayashi, M.; Murakami, N. New rev-export inhibitor from alpinia galanga and structure-activity relationship. Bioorg. Med. Chem. Lett. 2009, 19, 2555–2557.
212. Murakami, N.; Sugimoto, M.; Kobayashi, M. Participation of the β-hydroxyketone part for potent cytotoxicity of callystatin a, a spongean polyketide. Bioorg. Med. Chem. 2001, 9, 57–67.
213. Kalesse, M.; Chary, K.P.; Quitschalle, M.; Burzlaff, A.; Kasper, C.; Scheper, T. The total synthesis of (−)-callystatin a. Chemistry 2003, 9, 1129–1136.
214. Langille, N.F.; Panek, J.S. Total synthesis of (−)-callystatin a. Org. Lett. 2004, 6, 3203–3206.
215. Hayakawa, Y.; Sohda, K.; Furihata, K.; Kuzuyama, T.; Shin-ya, K.; Seto, H. Studies on new antitumor antibiotics, leptofuranins A, B, C and D.I. Taxonomy, fermentation, isolation and biological activities. J. Antibiot. (Tokyo) 1996, 49, 974–979.
216. Hayakawa, Y.; Sohda, K.; Seto, H. Studies on new antitumor antibiotics, leptofuranins A, B, C and D II. Physiocochemical properties and structure elucidation. J. Antibiot. (Tokyo) 1996, 49, 980–984.
217. Sakakibara, K.; Saito, N.; Sato, T.; Suzuki, A.; Hasegawa, Y.; Friedman, J.M.; Kufe, D.W.; Vonhoff, D.D.; Iwami, T.; Kawabe, T. Cbs9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 2011, 118, 3922–3931.
218. Almholt, D.L.; Loechel, F.; Nielsen, S.J.; Krog-Jensen, C.; Terry, R.; Bjorn, S.P.; Pedersen, H.C.; Praestegaard, M.; Moller, S.; Heide, M. et al. Nuclear export inhibitors and kinase inhibitors identified using a mapk-activated protein kinase 2 redistribution screen. Assay Drug Dev. Technol. 2004, 2, 7–20.
219. Kau, T.R.; Schroeder, F.; Ramaswamy, S.; Wojciechowski, C.L.; Zhao, J.J.; Roberts, T.M.; Clardy, J.; Sellers, W.R.; Silver, P.A. A chemical genetic screen identifies inhibitors of regulated nuclear export of a forkhead transcription factor in pten-deficient tumor cells. Cancer Cell 2003, 4, 463–476.
220. Salas Fragomeni, R.A.; Chung, H.W.; Landesman, Y.; Senapedis, W.; Saint-Martin, J.R.; Tsao, H.; Flaherty, K.T.; Shacham, S.; Kauffman, M.; Cusack, J.C. CRM1 and braf inhibition synergize and induce tumor regression in braf-mutant melanoma. Mol. Cancer Ther. 2013, 12, 1171–1179.
221. Abraham, S.A.; Holyoake, T.L. Redirecting traffic using the XPO1 police. Blood 2013, 122, 2926–2928.
222. Wettersten, H.I.; Landesman, Y.; Friedlander, S.; Shacham, S.; Kauffman, M.; Weiss, R.H. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth. PLoS ONE 2014, 9, e113867.
223. De Cesare, M.; Cominetti, D.; Doldi, V.; Lopergolo, A.; Deraco, M.; Gandellini, P.; Friedlander, S.; Landesman, Y.; Kauffman, M.G.; Shacham, S. et al. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: The role of survivin. Oncotarget 2015, 6, 13119–13132.
224. Niu, M.; Chong, Y.; Han, Y.; Liu, X. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells. Cancer Biol. Ther. 2015, 16, 1110–1118.
225. Senapedis, W.T.; Baloglu, E.; Landesman, Y. Clinical translation of nuclear export inhibitors in cancer. Semin. Cancer Biol. 2014, 27, 74–86.
226. Das, A.; Wei, G.; Parikh, K.; Liu, D. Selective inhibitors of nuclear export (sine) in hematological malignancies. Exp. Hematol. Oncol. 2015, 4, 7, doi:10.1186/s40164-015-0002-5.
227. Ishizawa, J.; Kojima, K.; Hail, N., Jr.; Tabe, Y.; Andreeff, M. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein. Pharmacol. Ther. 2015, 153, 25–35.
228. Parikh, K.; Cang, S.; Sekhri, A.; Liu, D. Selective inhibitors of nuclear export (sine)—A novel class of anti-cancer agents. J. Hematol. Oncol. 2014, 7, 78, doi:10.1186/s13045-014-0078-0.
229. Kazim, S.; Malafa, M.P.; Coppola, D.; Husain, K.; Zibadi, S.; Kashyap, T.; Crochiere, M.; Landesman, Y.; Rashal, T.; Sullivan, D.M. et al. Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic cancer. Mol. Cancer Ther. 2015, 14, 1570–1581.
230. Hing, Z.A.; Mantel, R.; Beckwith, K.A.; Guinn, D.; Williams, E.; Smith, L.L.; Williams, K.; Johnson, A.J.; Lehman, A.M.; Byrd, J.C. et al. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood 2015, 125, 3128–3132.
231. Bernad, R.; van der Velde, H.; Fornerod, M.; Pickersgill, H. Nup358/ RanBP2 attaches to the nuclear pore complex via association with Nup88 and Nup214/can and plays a supporting role in CRM1-mediated nuclear protein export. Mol. Cell Biol. 2004, 24, 2373–2384.
232. Hutten, S.; Kehlenbach, R.H. Nup214 is required for CRM1-dependent nuclear protein export in vivo. Mol. Cell Biol. 2006, 26, 6772–6785.
233. Roth, P.; Xylourgidis, N.; Sabri, N.; Uv, A.; Fornerod, M.; Samakovlis, C. The drosophila nucleoporin DNUP88 localizes DNUP214 and CRM1 on the nuclear envelope and attenuates nes-mediated nuclear export. J. Cell Biol. 2003, 163, 701–706.
234. Zhao, C.L.; Mahboobi, S.H.; Moussavi-Baygi, R.; Mofrad, M.R. The interaction of CRM1 and the nuclear pore protein tpr. PLoS ONE 2014, 9, e93709.
235. Waldmann, I.; Spillner, C.; Kehlenbach, R.H. The nucleoporin-like protein NLP1 (HCG1) promotes CRM1-dependent nuclear protein export. J. Cell Sci. 2012, 125, 144–154.
236. Takeda, A.; Sarma, N.J.; Abdul-Nabi, A.M.; Yaseen, N.R. Inhibition of CRM1-mediated nuclear export of transcription factors by leukemogenic Nup98 fusion proteins. J. Biol. Chem. 2010, 285, 16248–16257.
237. Roloff, S.; Spillner, C.; Kehlenbach, R.H. Several phenylalanine-glycine motives in the nucleoporin Nup214 are essential for binding of the nuclear export receptor CRM1. J. Biol. Chem. 2013, 288, 3952–3963.
238. Oka, M.; Asally, M.; Yasuda, Y.; Ogawa, Y.; Tachibana, T.; Yoneda, Y. The mobile fg nucleoporin NUP98 is a cofactor for CRM1-dependent protein export. Mol. Biol. Cell 2010, 21, 1885–1896.
239. Bernad, R.; Engelsma, D.; Sanderson, H.; Pickersgill, H.; Fornerod, M. Nup214- Nup88 nucleoporin subcomplex is required for CRM1-mediated 60 s preribosomal nuclear export. J. Biol. Chem. 2006, 281, 19378–19386.